Insiders the Biggest Winners as Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Market Cap Rises to CN¥17b
Insiders the Biggest Winners as Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Market Cap Rises to CN¥17b
Key Insights
主要见解
- Insiders appear to have a vested interest in Shenzhen Kangtai Biological Products' growth, as seen by their sizeable ownership
- 50% of the business is held by the top 6 shareholders
- Ownership research along with analyst forecasts data help provide a good understanding of opportunities in a stock
- 内部人似乎对康泰生物的增长有着极大的利益,可以看出他们持有的股份规模不小。
- 前六大股东持有该业务的50%股份。
- 所有权研究和分析师预测数据有助于更好地了解股票市场的机会。
To get a sense of who is truly in control of Shenzhen Kangtai Biological Products Co., Ltd. (SZSE:300601), it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are individual insiders with 48% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
要了解真正控制康泰生物的是谁,重要的是要了解业务的所有权结构。持有最大股份的是个人内部人员,占48%的股权。换句话说,这个群体将从他们对公司的投资中获得或承担最大的风险。
Clearly, insiders benefitted the most after the company's market cap rose by CN¥570m last week.
显然,在上周公司市值上涨了57000万人民币后,内部人员收益最大。
Let's take a closer look to see what the different types of shareholders can tell us about Shenzhen Kangtai Biological Products.
让我们仔细看看不同类型的股东对深圳康泰生物有什么样的信息可以提供给我们。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240712/0-104491a1bf79b8e8ba676ac41ea79f98-0-9d59eb22db193733fb6e2efcaf04e514.png/big)
What Does The Institutional Ownership Tell Us About Shenzhen Kangtai Biological Products?
从机构持股情况来看,可以告诉我们什么深圳康泰生物产品吗?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
许多机构衡量其业绩的标准是一个近似于当地市场的指数。因此,他们通常更加关注包括在主要指数中的公司。
We can see that Shenzhen Kangtai Biological Products does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Shenzhen Kangtai Biological Products' earnings history below. Of course, the future is what really matters.
我们可以看出,深圳康泰生物产品确实有机构投资者,并且他们持有公司股票的一个很大的部分。这意味着为这些机构工作的分析师已经看过股票,并且他们对它看好。但是就像其他人一样,他们可能也会犯错。如果多个机构同时改变对某只股票的观点,您可能会看到股价迅速下跌。因此,下面值得关注深圳康泰生物产品的盈利历史。当然,未来才是真正重要的。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240712/0-104491a1bf79b8e8ba676ac41ea79f98-1-2034e370dbcbbc5f590ee3337bd3b5f8.png/big)
We note that hedge funds don't have a meaningful investment in Shenzhen Kangtai Biological Products. Looking at our data, we can see that the largest shareholder is Weimin Du with 25% of shares outstanding. Liping Yuan is the second largest shareholder owning 19% of common stock, and Haifa Zheng holds about 2.2% of the company stock.
我们注意到对于深圳康泰生物,对冲基金并没有实质性的投资。根据我们的数据,最大的股东是Weimin Du,持有25%的流通股。Liping Yuan是第二大股东,持有19%的普通股,而Haifa Zheng持有公司股份的约2.2%。
We also observed that the top 6 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.
我们还观察到,前6大股东持有超过一半的股份登记簿,有一些较小的股东来平衡较大股东的利益。
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.
研究机构所有权是衡量和过滤股票预期表现的好方法。通过研究分析师的情绪也可以实现同样的目的。由于有相当数量的分析师涵盖这支股票,因此了解他们对未来的整体看法可能会有所帮助。
Insider Ownership Of Shenzhen Kangtai Biological Products
深圳康泰生物的内部股权
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
虽然内部人员的具体定义可能是主观的,但几乎所有人都认为董事会成员是内部人员。公司管理层应向董事会回答问题,后者应代表股东的利益。值得注意的是,有时高层管理人员也会成为董事会成员。
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
当内部人持股情况表明领导层思考和公司真正所有者一样时,内部所有权是积极的。然而,高达内部人士所有权也可能为公司内的小团体带来巨大的权力。在某些情况下,这可能是负面的。
Our most recent data indicates that insiders own a reasonable proportion of Shenzhen Kangtai Biological Products Co., Ltd.. It has a market capitalization of just CN¥17b, and insiders have CN¥8.4b worth of shares in their own names. That's quite significant. Most would be pleased to see the board is investing alongside them. You may wish to access this free chart showing recent trading by insiders.
我们最近的数据显示,内部人士拥有深圳康泰生物产品股份有限公司相当比例的股份。它的市值只有170亿元人民币,而内部人士拥有84亿元人民币的股份。这相当可观。大多数人会很高兴看到董事会与他们一起投资。您可能希望查看这份免费的图表,显示内部人士最近的交易。
General Public Ownership
一般大众所有权
With a 43% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Shenzhen Kangtai Biological Products. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
持有43%股份的普通公众,主要由个人投资者组成,对深圳康泰生物产品有一定程度的影响力。虽然这个群体不能必然主导局面,但肯定对公司的经营产生实际影响。
Next Steps:
下一步:
It's always worth thinking about the different groups who own shares in a company. But to understand Shenzhen Kangtai Biological Products better, we need to consider many other factors. To that end, you should be aware of the 2 warning signs we've spotted with Shenzhen Kangtai Biological Products .
考虑到公司的不同股东群体是一件值得思考的事情。但是要更好地了解康泰生物,我们需要考虑许多其他因素。为此,您应该注意我们在康泰生物中发现的2个警告信号。
But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.
但最终,决定该业务所有者将获得多大利益的是未来而非过去。因此,我们认为最好查看此免费报告,以了解分析师是否预测更光明的未来。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。